ExteNET Study Group 2021, ' Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial ', Clinical Breast Cancer, vol. 21, no. 1, pp. 80-91.e7 . https://doi.org/10.1016/j.clbc.2020.09.014 Chan, A, Moy, B, Mansi, J, Ejlertsen, B, Holmes, F A, Chia, S, Iwata, H, Gnant, M, Loibl, S, Barrios, C H, Somali, I, Smichkoska, S, Martinez, N, Alonso, M G, Link, J S, Mayer, I A, Cold, S, Murillo, S M, Senecal, F, Inoue, K, Ruiz-Borrego, M, Hui, R, Denduluri, N, Patt, D, Rugo, H S, Johnston, S R D, Bryce, R, Zhang, B, Xu, F, Wong, A, Martin, M & ExteNET Study Group 2021, ' Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial ', Clinical Breast Cancer, vol. 21, no. 1, pp. 80-91.e7 . https://doi.org/10.1016/j.clbc.2020.09.014